Arredouani MS - Search Results

1

Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice.

Arredouani MS, Tseng-Rogenski SS, Hollenbeck BK, Escara-Wilke J, Leander KR, Defeo-Jones D, Hwang C, Sanda MG. Arredouani MS, et al. Prostate. 2010 Jun 15;70(9):1002-11. doi: 10.1002/pros.21134. Prostate. 2010. PMID: 20209643 Free PMC article.

2

Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.

Neeley YC, Arredouani MS, Hollenbeck B, Eng MH, Rubin MA, Sanda MG. Neeley YC, et al. Among authors: arredouani ms. Prostate. 2008 May 15;68(7):715-27. doi: 10.1002/pros.20689. Prostate. 2008. PMID: 18302222 Free article.

3

Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.

Haram KM, Peltier HJ, Lu B, Bhasin M, Otu HH, Choy B, Regan M, Libermann TA, Latham GJ, Sanda MG, Arredouani MS. Haram KM, et al. Among authors: arredouani ms. Prostate. 2008 Oct 1;68(14):1517-30. doi: 10.1002/pros.20803. Prostate. 2008. PMID: 18668517

4

Development of a peptide-based vaccine targeting TMPRSS2:ERG fusion-positive prostate cancer.

Kissick HT, Sanda MG, Dunn LK, Arredouani MS. Kissick HT, et al. Among authors: arredouani ms. Cancer Immunol Immunother. 2013 Dec;62(12):1831-40. doi: 10.1007/s00262-013-1482-y. Epub 2013 Oct 23. Cancer Immunol Immunother. 2013. PMID: 24149465 Free PMC article.

5

Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer.

Arredouani MS, Lu B, Bhasin M, Eljanne M, Yue W, Mosquera JM, Bubley GJ, Li V, Rubin MA, Libermann TA, Sanda MG. Arredouani MS, et al. Clin Cancer Res. 2009 Sep 15;15(18):5794-802. doi: 10.1158/1078-0432.CCR-09-0911. Epub 2009 Sep 8. Clin Cancer Res. 2009. PMID: 19737960 Free PMC article.

6

The role of the transcription factor SIM2 in prostate cancer.

Lu B, Asara JM, Sanda MG, Arredouani MS. Lu B, et al. Among authors: arredouani ms. PLoS One. 2011;6(12):e28837. doi: 10.1371/journal.pone.0028837. Epub 2011 Dec 9. PLoS One. 2011. PMID: 22174909 Free PMC article.

7

Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.

Kissick HT, Sanda MG, Dunn LK, Arredouani MS. Kissick HT, et al. Among authors: arredouani ms. PLoS One. 2014 Apr 1;9(4):e93231. doi: 10.1371/journal.pone.0093231. eCollection 2014. PLoS One. 2014. PMID: 24690990 Free PMC article.

8

Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation.

Kissick HT, Sanda MG, Dunn LK, Pellegrini KL, On ST, Noel JK, Arredouani MS. Kissick HT, et al. Among authors: arredouani ms. Proc Natl Acad Sci U S A. 2014 Jul 8;111(27):9887-92. doi: 10.1073/pnas.1402468111. Epub 2014 Jun 23. Proc Natl Acad Sci U S A. 2014. PMID: 24958858 Free PMC article.

9

Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancer.

Tseng-Rogenski SS, Arredouani MS, Neeley YC, Lu B, Chinnaiyan AM, Sanda MG. Tseng-Rogenski SS, et al. Among authors: arredouani ms. Cancer Immunol Immunother. 2008 Sep;57(9):1357-65. doi: 10.1007/s00262-008-0471-z. Epub 2008 Feb 12. Cancer Immunol Immunother. 2008. PMID: 18265979 Free PMC article.

10

A safety-modified SV40 Tag developed for human cancer immunotherapy.

Tseng-Rogenski SS, Arredouani MS, Escara-Wilke JF, Neeley YC, Imperiale MJ, Sanda MG. Tseng-Rogenski SS, et al. Among authors: arredouani ms. Drug Des Devel Ther. 2009 Feb 6;2:17-24. Drug Des Devel Ther. 2009. PMID: 19920890 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

40 results

Search Page